The handheld tactical spotlight is built for safe and easy charging. It includes a single 3.7v rechargeable mAh protected lithium-ion battery. Green light indicator will show when it's fully charged. Count on the Tac9er rechargeable flashlight as an essential everyday carry tool for security, emergencies, survival and rescue. Brinkmann Qbeam Max Million III 3 Million Maxpower Spotlight, Powerful 1200 Lumen Spotlight Bright Portable High Intensity Halogen Spotlight Offroad Automotive/Emergency/Boating 800-2301-0. 4.4 out of 5 stars 407. Join Prime to save $6.60 on this item. The nonattendance rate was a bit higher than anticipated, however, resulting in one session with 6 observers, five sessions with 5, seven sessions with 4, and one session each with 3 and 2. On arrival, the observers were led to a laboratory room and asked to take a seat at a long table in the center of the room. The handheld tactical spotlight is built for safe and easy charging. It includes a single 3.7v rechargeable mAh protected lithium-ion battery. Green light indicator will show when it's fully charged. Count on the Tac9er rechargeable flashlight as an essential everyday carry tool for security, emergencies, survival and rescue. In the US and Canada vehicles over 80 inches (2.032 m) wide must be equipped with three amber front and three red rear identification lamps spaced 6–12 inches (15–30 cm) apart at the centre of the front and rear of the vehicle, as high as practicable. The front identification lamps are typically mounted atop the cab of vehicles.
Back to Journals » Clinical and Experimental Gastroenterology » Volume 10
AuthorsFragkos KC
Received29 May 2017
Accepted for publication 10 September 2017
Published 25 September 2017 Volume 2017:10 Pages 229—240
DOIhttps://doi.org/10.2147/CEG.S123621
Checked for plagiarism Yes
Review bySingle anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Wing-Kin Syn
Konstantinos C Fragkos
Gastrointestinal Services, University College London Hospitals, London, UK Background: Irritable bowel syndrome with diarrhea (IBS-D) has limited options for treatment currently, including mainly anti-motility medications, antispasmodics, and antidepressants. This review discusses the properties of a new drug, eluxadoline, a gut-targeting mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist, and its efficacy and safety in patients with IBS-D. Materials and methods: A systematic review of the literature was undertaken to identify studies that had investigated eluxadoline as a treatment in IBS-D. A narrative review of other information is provided with respect to pharmacological and chemical properties. Where suitable, meta-analysis was performed with a random-effects model to produce a pooled estimate. Results: Eluxadoline showed efficacy improving stool consistency (standardized mean difference [SMD]: -0.29 at 12 weeks, p = 0.0004; -0.46 at 26 weeks, p = 0.0001), global symptoms (SMD: -0.15 at 12 weeks, p = 0.006; -0.14 at 26 weeks, p = 0.02), quality of life (SMD: 0.21 at 12 weeks, p < 0.0001; 0.16 at 26 weeks, p = 0.007), pain (SMD: -0.17 at 12 weeks, p = 0.001; -0.16 at 26 weeks, p = 0.01), and adequate relief (odds ratio [OR]: 1.99 at 12 weeks, p < 0.00001; 1.78 at 26 weeks, p < 0.0001). It also improved IBS severity and other abdominal symptoms such as bloating, discomfort, and risk of urgency and fecal incontinence. Its main side effects included constipation (OR: 3.49, p < 0.00001), vomiting (OR: 3.42, p = 0.0002), abdominal pain (OR: 1.78, p = 0.007), and nausea (OR: 1.42, p = 0.07). The overall quality of trials was satisfactory with the meta-analyses providing largely homogeneous outcomes. Conclusion: Eluxadoline’s place in clinical practice might prove useful since the pharmacological options of IBS-D are limited and eluxadoline showed a positive effect in treating the symptoms of IBS-D. Keywords: eluxadoline, irritable bowel syndrome, diarrhea, stool consistency, pain
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Download Article [PDF]
Houdahspot 3 6 4 – Advanced Front End For Spotlight LightView Full TextHoudahspot 3 6 4 – Advanced Front End For Spotlight Trailer[HTML]Houdahspot 3 6 4 – Advanced Front End For Spotlight Lighting[Machine readable]Comments are closed.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |